000142878 001__ 142878
000142878 005__ 20240229112533.0
000142878 0247_ $$2doi$$a10.1158/1078-0432.CCR-18-0777
000142878 0247_ $$2pmid$$apmid:30327309
000142878 0247_ $$2ISSN$$a1078-0432
000142878 0247_ $$2ISSN$$a1557-3265
000142878 0247_ $$2altmetric$$aaltmetric:49814389
000142878 037__ $$aDKFZ-2019-00508
000142878 041__ $$aeng
000142878 082__ $$a610
000142878 1001_ $$aVeldwijk, Marlon R$$b0
000142878 245__ $$aAssociation of CD4+ Radiation-Induced Lymphocyte Apoptosis with Fibrosis and Telangiectasia after Radiotherapy in 272 Breast Cancer Patients with >10-Year Follow-up.
000142878 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2019
000142878 3367_ $$2DRIVER$$aarticle
000142878 3367_ $$2DataCite$$aOutput Types/Journal article
000142878 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634561459_4000
000142878 3367_ $$2BibTeX$$aARTICLE
000142878 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142878 3367_ $$00$$2EndNote$$aJournal Article
000142878 520__ $$aRadiation-induced lymphocyte apoptosis (RILA) has been suggested as a predictive assay for adverse late reactions after radiotherapy. Thus, low RILA values of T-lymphocyte subpopulations have been associated with increased risk for various endpoints at 2 to 3 years of follow-up. The purpose was to test if such associations persist for specific endpoints (subcutaneous fibrosis, telangiectasia) in breast cancer patients with at least 10 years of follow-up.Experimental Design: Two hundred and seventy-two female patients who had received breast-conserving therapy within the German ISE study were included (median follow-up: 11.6 years). Radiotherapy-induced side effects were scored according to the Late Effects in Normal Tissues-Subjective, Objective, Management, and Analytic (LENT-SOMA) classification system. RILA in the CD4+, CD8+, and natural killer (NK) subpopulations from peripheral blood was analyzed by flow cytometry. Multivariate predictive modeling was performed including relevant clinical risk factors.Low CD4+ RILA was associated with increased risk for both fibrosis (P = 0.011) and telangiectasia (P < 0.001). For fibrosis, the association was stronger outside the surgical area (Fibout; P = 0.004) than within (Fibin; P = 0.17). Predictive multivariate modeling including clinical risk factors yielded OR of 3.48 (95% confidence interval, 1.84-6.58) for any fibrosis and 8.60 (2.71-27.3) for telangiectasia. Addition of CD4+ RILA to the clinical variables improved discrimination (c statistics) from 0.62 to 0.68 for any fibrosis, 0.62 to 0.66 for Fibin, 0.61 to 0.69 for Fibout, and from 0.65 to 0.76 for telangiectasia. CD8+ and NK RILA were not significantly associated with radiotherapy-related late reactions.The results provide first evidence that low CD4+ RILA is associated with increased subcutaneous fibrosis and telangiectasia even after 10 years. This supports the potential usefulness for predicting individual clinical risk.
000142878 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000142878 588__ $$aDataset connected to CrossRef, PubMed,
000142878 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b1
000142878 7001_ $$0P:(DE-He78)5444d70823957b5081dfd421dbfed155$$aBotma, Akke$$b2
000142878 7001_ $$0P:(DE-He78)6463d23a85ce9e7ecc93b32fc2b4d25f$$aHelmbold, Irmgard$$b3
000142878 7001_ $$aSperk, Elena$$b4
000142878 7001_ $$aGiordano, Frank A$$b5
000142878 7001_ $$aGürth, Nicole$$b6
000142878 7001_ $$aKirchner, Anne$$b7
000142878 7001_ $$aBehrens, Sabine$$b8
000142878 7001_ $$00000-0001-6037-0853$$aWenz, Frederik$$b9
000142878 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b10$$eLast author
000142878 7001_ $$00000-0001-6554-5907$$aHerskind, Carsten$$b11
000142878 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-18-0777$$gVol. 25, no. 2, p. 562 - 572$$n2$$p562 - 572$$tClinical cancer research$$v25$$x1557-3265$$y2019
000142878 909CO $$ooai:inrepo02.dkfz.de:142878$$pVDB
000142878 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142878 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5444d70823957b5081dfd421dbfed155$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142878 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6463d23a85ce9e7ecc93b32fc2b4d25f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000142878 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000142878 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000142878 9141_ $$y2019
000142878 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2017
000142878 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142878 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142878 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142878 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142878 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142878 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142878 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142878 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142878 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142878 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2017
000142878 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000142878 980__ $$ajournal
000142878 980__ $$aVDB
000142878 980__ $$aI:(DE-He78)C020-20160331
000142878 980__ $$aUNRESTRICTED